SCHEMBL2818286

SCHEMBL2818286

CC(C)c1cccc(C(C)C)c1-c1c(N)ccc2c1C(=O)NC2=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
CASP7 P55210 2/20 0.45
USP2 O75604 2/20 0.45
POLB P06746 2/20 0.45
MAPT P10636 2/20 0.45
THRB P10828 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
RGS12 O14924 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
APEX1 P27695 1/20 0.45
CASP1 P29466 1/20 0.45
BRCA1 P38398 1/20 0.45
MTOR P42345 1/20 0.45
RECQL P46063 1/20 0.45
BLM P54132 1/20 0.45
GNAI1 P63096 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL166123 0.83 HPGD (0.47) PARP1MEN1KMT2ACASP7USP2
SCHEMBL173290 0.83 ANPEP (0.43) PARP1MEN1KMT2ACASP7USP2
SCHEMBL14562917 0.81 GABRA1 (0.46) THRBCYP1A2CYP3A4BLMANPEP
SCHEMBL2820121 0.80 HPGD (0.45) PARP1MEN1KMT2ACASP7USP2
SCHEMBL6468586 0.80 PARP1 (0.50) PARP1MEN1KMT2ACASP7USP2
SCHEMBL2820310 0.80 SMN1; SMN2 (0.44) MEN1KMT2APOLBMAPTCYP3A4
SCHEMBL5326248 0.77 PARP1 (0.39) PARP1MEN1KMT2ACASP7USP2
SCHEMBL22525287 0.77 CASP3 (0.52) PARP1CASP7ANPEPMAOAALDH1A1
SCHEMBL29372946 0.74 PARP1 (0.53) PARP1MEN1KMT2ACASP7USP2
SCHEMBL221618 0.74 PARP1 (0.53) PARP1MEN1KMT2ACASP7USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008154353-A1 THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES CHARLESSON, LLC (US) 2008-12-18 WO claimed
US-20080306134-A1 THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES CHARLESSON, LLC 2008-12-11 US claimed
CN-101904841-B Phthalide imide analogue and application thereof in preparing medicine for treating diabetic macular edema DANYANG CHEN 2012-09-19 CN disclosed
CN-102503884-A Synthesis method of phenylphthalimide analog DANYANG CHEN 2012-06-20 CN disclosed
US-20100247659-A1 PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA CHARLESSON, LLC (US) 2010-09-30 US disclosed
US-20100247659-A1 PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA CHARLESSON, LLC (US) 2010-09-30 US disclosed
WO-2008154353-A1 THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES CHARLESSON, LLC (US) 2008-12-18 WO disclosed
US-20080306134-A1 THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES CHARLESSON, LLC 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100247659-A1 PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA SLC2A8, VEGFA, SLC2A1 PARP1 1892/4885MEN1 3601/4885KMT2A 3840/4885
US-20080306134-A1 THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES VEGFA, FLT1, VCAM1 PARP1 4318/4885MEN1 1218/4885KMT2A 2668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.